Skip to main content
SpringerLink
Log in

Alcune considerazioni su HTA e innovazione

  • Editoriale
  • Published:
PharmacoEconomics Italian Research Articles

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Pharmaceuticalpriceregulationscheme/index.htm

  2. Brouwer WB, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 2000; 19: 439–59

    Article  PubMed  CAS  Google Scholar 

  3. Brouwer WB, Culyer AJ, van Exel NJ, et al. Welfarism vs. extra-welfarism. J Health Econ 2008; 27: 325–38

    Article  PubMed  Google Scholar 

  4. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271–92

    Article  PubMed  Google Scholar 

  5. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53–72

    Article  PubMed  CAS  Google Scholar 

  6. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: health utilities index. Pharmacoeconomics 1995; 7: 503–20

    Article  PubMed  CAS  Google Scholar 

  7. Conigliani C, Tancredi A, Manca A. Il metodo bayesiano per le analisi decisionali in sanità. Pharmacoeconomics-Italian Research Articles 2010; 12: 1–4

    Google Scholar 

  8. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733–44

    Article  PubMed  Google Scholar 

  9. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 2007; 12: 56–8

    Article  PubMed  Google Scholar 

  10. Jena AB, Philipson TJ. Cost effectiveness analysis and innovation. J Health Econ 2008; 27: 1224–36

    Article  PubMed  Google Scholar 

  11. Garrison Jr LP. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle. Oncologist 2010; 15 Suppl. 1: 49–57

    Article  PubMed  Google Scholar 

  12. Lucioni C, Mazzi SF, Polcaro F. Il risk sharing come applicazione del value based pricing. Pharmacoeconomics-Italian Research Articles 2010; 12: 71–80

    Google Scholar 

  13. Pammolli F, Oglialoro C, Salerno N. Strumenti di regolazione del mercato farmaceutico: un’analisi ragionata. Quaderni CERM n. 3, 2004

  14. Office of Fair Trading. The pharmaceutical price regulation scheme. An OFT market study. London, 2007

    Google Scholar 

  15. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251–4

    Article  PubMed  Google Scholar 

  16. Jayadev A, Stiglitz J. Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Aff (Millwood) 2009; 28(1): w165–168

    Article  Google Scholar 

  17. Claxton K. OFT, VBP: QED? Health Econ 2007; 16: 545–58

    Article  PubMed  Google Scholar 

  18. UK Department of Health. A new value-based approach to the pricing of branded medicines. London, 2010. Disponibile sul sito: http://www.dh.gov.uk/en/Consultations

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, The University of York, UK

    Andrea Manca

Authors
  1. Andrea Manca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manca, A. Alcune considerazioni su HTA e innovazione. Pharmacoeconomics-Ital-Res-Articles 14, 1–2 (2012). https://doi.org/10.1007/BF03320690

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320690

Search

Navigation